ArticleAge and ageing2025
Downstream of hearing loss: a population-based multistate analysis of lifetime risk and years lived with hearing loss, dementia and their comorbidity in Finland.
Article in Age and ageing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHearing loss (HL) is a major modifiable risk factor of dementia, yet gaps persist regarding its association with years lived with dementia, lifetime risk differences by HL status, and sociodemographic disparities.
methodsUsing Finnish register data on all residents aged 60-99 from 2009-2019 (N=1,987,876; 16,439,107 person-years) and discrete-time multistate modeling, we calculated age-specific transition probabilities between five states - healthy, HL, dementia, comorbidity (both HL and dementia), and death, stratified by sex and education. We then estimated state-specific expectancies and lifetime risk.
resultsAt age 60, males and females in the overall population were expected to live 3.39 and 3.61 years with HL, and 1.09 and 1.85 years with dementia, respectively. Lifetime risk of HL was 22.7% for both sexes; dementia risk was 21.4% for males and 31.0% for females. When examining subpopulations defined by origin state at age 60, those who were healthy could expect 1.10 (males) and 1.89 (females) years with dementia. Meanwhile, those with HL at age 60: 1.90 years (males) and 2.82 years (females) with both HL and dementia (comorbidity). Their lifetime risk of comorbidity was 33.5% (males) and 42.9% (females) - about 1.5 times higher than the dementia risk for those starting healthy. Higher education was associated with longer life, more years across all states, and higher lifetime risks.
conclusionsThese findings illustrate how HL at age 60 is associated with a redistribution of remaining years toward dementia, providing new insight into the joint burden of sensory and cognitive aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.